Our news and events
Enodia Therapeutics Strengthens Sec61 Portfolio Through Acquisition of Preclinical Assets from Kezar Life Sciences
Enodia Therapeutics acquires Sec61 preclinical assets from Kezar Life Sciences to expand its targeted protein degradation platform and accelerate development of small-molecule inhibitors.
Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform
Enodia Therapeutics Secures €20.7M to Advance a Small-Molecule Platform for Targeted Protein Degradation Enabled by Proteomics and Machine Learning Seed round co-led by Elaia, Pfizer Ventures and Bpifrance Machine-learning platform enables signal peptide-informed...
Enodia Therapeutics at JPM 2026
Enodia Therapeutics will be attending JPM 2026 in San Francisco from January 13–16, 2026. Yves Ribeill (CEO) and Oscar Castanon (Business Developer) will be available to connect throughout the week.If you would like to schedule a meeting during the conference,...
Argobio and the Institut Pasteur launch Enodia Therapeutics
Argobio and the Institut Pasteur launch Enodia Therapeutics: A biotech company with a new approach for Targeted protein Degradation Turning groundbreaking research from the Institut Pasteur with the support of Argobio's start-up studio, into novel treatments for...